Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
530 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.56 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 26.62 | Oscillator | Neutral |
| Williams %R (14) | -91.47 | Oscillator | Buy |
| MACD (12, 26, 9) | -2.45 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 24.00 (+DI 17.9 / -DI 30.8) | Trend | Sell |
Current price $48.50
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 |
| EMA 20 | 53.45 | MA | Strong Sell |
| SMA 20 | 53.72 | MA | Strong Sell |
| EMA 50 | 56.27 | MA | Strong Sell |
| SMA 50 | 59.23 | MA | Strong Sell |
| SMA 200 | 45.13 | MA | Strong Buy |
| Stifel |
| maintain |
| Buy |
| Buy |
| Oct 2, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 10, 26 | Truist Securities | maintain | Buy | Buy |
| Jul 29, 26 | Mizuho | maintain | Outperform | Outperform |
| May 12, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| May 12, 26 | Barclays | maintain | Overweight | Overweight |
| May 11, 26 | Truist Securities | maintain | Buy | Buy |
| Jan 16, 26 | Guggenheim | maintain | Buy | Buy |
| Dec 19, 25 | Stifel | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 20, 26 | Radovich Peter | director | A-Award | 18,200 @ $53.50 | $973.7K |
| Oct 20, 26 | Radovich Peter | 0 | — | ||
| Aug 4, 26 | Azoulay Salomon | officer: Chief Medical Officer | S-Sale | 370 @ $65.77 | $24.33K |
| Aug 3, 26 | Smither John W | officer: Chief Financial Officer | A-Award | 130,000 @ $64.41 | $8.37M |
| Aug 3, 26 | Smither John W | officer: Chief Financial Officer | A-Award | 28,000 | — |
| Aug 3, 26 | Hoerter Steven L. | director, officer: President and CEO | A-Award | 331,000 @ $64.41 | $21.32M |
| Aug 3, 26 | Hoerter Steven L. | director, officer: President and CEO | A-Award | 71,000 | — |
| Jun 4, 26 | Mathers Edward T | director | A-Award | 12,500 @ $30.91 | $386.4K |
TTM vs. 5-year historical average (annual ratios)
| Metric | MBX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -20.2x | -18.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -15.8x | EPS est. -3.07 | Discount |
| Price / Book | 5.6x | -5.6x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -21.2x | -18.1x | Elevated |
| Return on equity | -26.0% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.01 | -0.00 | Conservative |
| Piotroski / Altman Z | 1/9 | Z 53.55 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending IPVS 2026 and presenting results of a novel synthetic vaginal matrix designed to assist with validation and ongoing quality management of HPV molecular assays used in cervical cancer screening programs. IPVS 2026 is the 38th annual conference of the International Papillomavirus Society, taking place in Athens, Greece October 22-25, 2026.
CARMEL, Ind. and BURLINGTON, Mass.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.63 | -0.78 | Miss -23.3% | — |
| May 7, 2026 | -0.62 | -0.51 | Beat 17.7% | — |
| Mar 12, 2026 | -0.64 | -0.49 | Beat 23.4% | — |
| Nov 6, 2025 | -0.73 | -0.63 | Beat 13.7% | — |
| Aug 7, 2025 | -0.77 | -0.58 | Beat 24.7% | — |
| May 12, 2025 | -0.81 | -0.71 | Beat 12.3% | — |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 08:27:37 | View |
| SC 13D/A | Aug 10, 2026 | 2026-08-10 17:35:46 | View |
| SC 13D/A | Aug 10, 2026 | 2026-08-10 16:44:26 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 08:06:31 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 08:03:59 | View |
| 4 | Aug 5, 2026 | 2026-08-05 16:57:04 | View |
Proxy statement (DEF 14A) disclosures
